REFERENCES
- Simoens S, Decramer M, Laekeman G. Economic aspects of antimicrobial therapy of acute exacerbations of COPD. Respir Med 2007; 101:15–26.
- Toy E, The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD 2010; 7:213–224.
- Drummond M, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. (2005). Methods for the economic evaluation of health care programmes; 3 ed. Oxford: Oxford University Press.
- Stein B, Charbeneau J, Lee T, Schumock G, Lindenauer P, Bautista A, Lauderdale D, Naureckas E, Krishnan J. Hospitalizations for acute exacerbations of chronic obstructive pulmonary disease: how you count matters. COPD 2010; 7:165–170.
- Buist AS, Vollmer WM, Sullivan SD, Weiss KB, Lee TA, Menezes AM, Crapo RO, Jensen RL, Burney PG. The burden of obstructive lung disease initiative (BOLD): rationale and design. COPD 2005; 2:277–283.
- Simoens S, Decramer M, De Coster S, Celis G, Laekeman G. Clinical and economic analysis of antimicrobial therapy of chronic obstructive pulmonary disease exacerbations. Int J Clin Pract 2007; 61:200–206.